title: [Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view].
abstract: Most cancers have a sporadic physiopathology, but approximately 5 to 10% of breast cancers and 10% of ovarian cancers involve a genetic predisposition. Sometimes, the gene involved in these hereditary cancers can be identified (usually BRCA1 or 2), but most of the time it remains unknown. However, all women considered at high risk, because of their familial history, must be identified so they can be provided with the most adequate care, since the probability is very high that they develop such a cancer in the future. Fortunately, effective strategies have been developed to reduce this risk. Early detection of breast cancer is possible and prophylactic treatments (chemoprevention and prophylactic surgery) exist for both breast and ovarian cancers. Another reason why it is essential that these high risk women are identified is that treatment for hereditary cancers differs in some ways from that of sporadic cancers. It is best that counseling be given in an interdisciplinary cancer genetic clinic, where all practionners are aware of the latest data and guidelines.
authors.affiliation: Service d'endocrinologie et médecine de la reproduction, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France. carine.courtillot@psl.aphp.fr
authors.forename: C
authors.initials: C
authors.lastname: Courtillot
authors.forename: P
authors.initials: P
authors.lastname: Touraine
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics*; D004704:Endocrinology / Q000379:methods; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D016158:Genes, p53; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics*; D051059:PTEN Phosphohydrolase / Q000235:genetics; D012307:Risk Factors
chemical_list: D051059:PTEN Phosphohydrolase